Christina Gillenwater, APRN
Adult Health · Hot Springs, ARNPI 1811326861
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 28.4% of the total.
Across 154 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$775
- AbbVie$366
- Dexcom, Inc.$322
- Merck$186
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$155
- Vanda Pharmaceuticals Inc.$146
- plus $785 from 15 others
What the payments were for
- Food & beverage$2,724100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $775 |
| AbbVie | 29 | $366 |
| Dexcom, Inc. | 21 | $322 |
| Merck | 9 | $186 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $155 |
| Vanda Pharmaceuticals Inc. | 6 | $146 |
| Otsuka America Pharmaceutical, Inc. | 9 | $142 |
| Lilly USA, LLC | 8 | $127 |
| Sumitomo Pharma America, Inc. | 6 | $74 |
| Novo Nordisk | 5 | $70 |
| Pfizer | 4 | $66 |
| Amgen(2 entities) | 4 | $61 |
| GSK | 3 | $49 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Lundbeck LLC | 2 | $37 |
| Boston Scientific | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Vertex | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,735 in reported general payments places this provider in the 80th percentile of 154 adult health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $56,081 |
| FarxigaDapagliflozin Propanediol | 28 | $20,498 |
| MounjaroTirzepatide | 15 | $15,227 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $14,788 |
| LinzessLinaclotide | 22 | $11,865 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,332 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 64 | $1,273 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $1,142 |
| Tizanidine Hcl | 68 | $874 |
| Duloxetine Hcl | 38 | $845 |
| Irbesartan | 41 | $778 |
| Methocarbamol | 43 | $715 |
| Cefdinir | 35 | $689 |
| Cyclobenzaprine Hcl | 55 | $687 |
| Rosuvastatin Calcium | 71 | $685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $70 | $56,08148 claims |
| AstraZenecaFarxiga | $775 | $20,49828 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $49 | $20,12033 claims |
| Lilly USA, LLCMounjaro | $127 | $15,22715 claims |
| AbbVieLinzess, Synthroid | $366 | $12,46134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 154 adult health providers in Arkansas.
Other adult health in Hot Springs
- Lisa HarveyHot Springs$8K
- Randy HallHot Springs$4K
- Ashley LoeHot Springs$3K
- Mitzi PruittHot Springs$1K
- Holly MooreLittle Rock$59K
- Deborah ShipmanJonesboro$41K
- Lisa HurdJonesboro$12K
- Kari SchrankFayetteville$9K
- Amanda McClureFayetteville$9K
- Gina NullFort Smith$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.